Lipids Blood Markers

Total amount of cholesterol in the blood.

PED: AAS generally worsen lipid profiles. Oral AAS are particularly harsh on lipids. Total cholesterol alone is less meaningful than the HDL/LDL ratio and ApoB.

High-density lipoprotein - 'good' cholesterol that protects against heart disease.

PED: CRITICAL: AAS (especially oral compounds) dramatically suppress HDL, often to dangerously low levels (<0.5 mmol/L). This is one of the most significant cardiovascular risks of AAS use. HDL should be monitored closely and given time to recover between cycles. HDL typically takes 4-8 weeks to recover after dropping oral compounds.

Low-density lipoprotein - 'bad' cholesterol associated with heart disease risk.

PED: AAS typically elevate LDL. Combined with suppressed HDL, this creates an atherogenic profile. ApoB is a more accurate measure of atherogenic particle count than LDL alone.

Type of fat in the blood. Elevated levels increase cardiovascular risk.

PED: Can be elevated by high calorie bulking diets, especially high carb. GH use can worsen triglycerides. Fasted blood draw important for accurate reading (12h fast minimum).

Total cholesterol minus HDL. Captures all atherogenic lipoproteins (LDL, VLDL, IDL).

PED: Better predictor of cardiovascular risk than LDL alone. AAS worsen this marker by suppressing HDL and elevating LDL/VLDL. Target <2.5 mmol/L for primary prevention. ApoB is an even more accurate cardiovascular risk marker -- consider requesting alongside lipid panel.

Ratio of total cholesterol to HDL. Lower is better for cardiovascular health.

PED: AAS users often have very unfavourable ratios due to suppressed HDL. Ratio >5.0 indicates elevated cardiovascular risk. Optimal is <4.0.

Protein found on all atherogenic lipoprotein particles (LDL, VLDL, IDL, Lp(a)). Each particle carries exactly one ApoB molecule, making it a direct count of atherogenic particles. Considered a more accurate cardiovascular risk predictor than LDL alone.

PED: Superior to LDL for assessing cardiovascular risk in PED users. AAS worsen ApoB levels -- oral compounds are particularly harmful. Unlike LDL (which measures cholesterol content), ApoB counts the actual number of atherogenic particles, which better predicts arterial plaque buildup. Target <0.9 g/L for primary prevention, <0.7 g/L for high-risk individuals.

Genetically determined lipoprotein particle. Elevated levels are an independent risk factor for cardiovascular disease, aortic stenosis, and stroke. Levels are ~90% determined by genetics and largely unaffected by lifestyle.

PED: Lp(a) is almost entirely genetic -- AAS, diet, and exercise have minimal effect on levels. However, it is a critical cardiovascular risk marker that every PED user should know once. If elevated (>75 nmol/L or >30 mg/dL), it compounds the already elevated cardiovascular risk from AAS-worsened lipids. Test once -- if normal, no need to retest as levels are stable throughout life.

The primary structural protein of HDL particles. Superior predictor of cardiovascular risk compared to HDL-C because it directly quantifies functional HDL particles.

PED: Oral 17-alpha-alkylated AAS devastate ApoA-1. Stanozolol reduced ApoA-1 by 40% in clinical studies — it upregulates hepatic triglyceride lipase (HTGL) by 230% within 3 days, accelerating HDL catabolism. Injectable testosterone at TRT doses has minimal effect. Nandrolone showed no significant change. Compounds ranked worst to least: Stanozolol > Oxandrolone > Oxymetholone > Trenbolone > Boldenone > Testosterone > Nandrolone. Recovery is slow — ApoA-1 had not returned to baseline 6 weeks after a 14-week cycle.

The balance between atherogenic particles (ApoB) and protective particles (ApoA-1). Considered the single most powerful lipid predictor of cardiovascular risk, superior to any cholesterol ratio.

PED: AAS users get a double hit — ApoB rises (more atherogenic particles) while ApoA-1 drops (fewer protective particles), amplifying the ratio dramatically. A baseline of 0.55 can easily reach 1.2+ on an oral AAS cycle. The INTERHEART study (52 countries) found ApoB/ApoA-1 superior to any cholesterol ratio for predicting myocardial infarction, with a population-attributable risk of 54%. This is the most important single lipid marker for PED users to track.

Total number of LDL particles measured by NMR spectroscopy. More predictive of cardiovascular disease than LDL cholesterol concentration alone.

PED: AAS significantly increase LDL particle number, even when LDL-C appears only mildly elevated. Oral 17-alpha-alkylated steroids have the most pronounced effect. Discordance between LDL-C and LDL-P is common in AAS users — LDL-P often reveals higher cardiovascular risk than LDL-C suggests. Combined with HDL suppression, this creates a highly atherogenic particle profile. Trenbolone is particularly harsh on lipoprotein particle counts.

Mean diameter of LDL particles. Pattern A (large buoyant, >20.5 nm) is less atherogenic; Pattern B (small dense, <20.5 nm) is associated with increased cardiovascular risk.

PED: AAS shift LDL toward small dense Pattern B particles, increasing atherogenicity even when total LDL-C is not dramatically elevated. Oral AAS (stanozolol, oxandrolone) cause the most pronounced shift to small dense LDL. Insulin resistance from GH/insulin use compounds this shift. High triglycerides correlate with smaller LDL. Pattern B + elevated LDL-P is the most concerning combination.

Total number of HDL particles. HDL-P is a stronger predictor of cardiovascular protection than HDL cholesterol concentration.

PED: AAS profoundly suppress HDL-P, often more dramatically than HDL-C. Oral AAS cause the most severe suppression. HDL-P is a better measure of reverse cholesterol transport capacity than HDL-C alone. On-cycle HDL-P values of 15-20 umol/L are common (vs normal >30). Recovery of HDL-P after cycle cessation can take 3-6 months.

Concentration of large VLDL particles. Elevated levels indicate triglyceride-rich lipoprotein overproduction and are strongly linked to insulin resistance.

PED: GH use increases hepatic VLDL production, elevating large VLDL-P. Insulin use (common in advanced bodybuilding) and insulin resistance from GH compound this. High-calorie bulking diets (especially high-carb) drive VLDL production. Oral AAS affect hepatic lipid metabolism, contributing to VLDL elevation. Elevated large VLDL-P correlates strongly with the LP-IR score.

Concentration of large HDL particles. These are the most cardioprotective HDL subclass, responsible for the majority of reverse cholesterol transport.

PED: AAS profoundly reduce large HDL-P — these particles are the first to decline on-cycle. Oral AAS have the most severe impact. Large HDL-P is the HDL subclass most associated with cardiovascular protection. On-cycle values often drop to near-zero. Recovery after cycle cessation is slow (3-6 months). Aerobic exercise is the strongest stimulus for large HDL-P production.

Mean diameter of VLDL particles. Larger VLDL particles are more triglyceride-rich and associated with insulin resistance and metabolic dysfunction.

PED: GH use and insulin resistance increase VLDL size by promoting hepatic production of large triglyceride-rich VLDL. High-calorie bulking diets (especially high-carb) increase VLDL size. Larger VLDL particles are a key driver of the LP-IR insulin resistance score. Combined with insulin and GH use in advanced bodybuilding, VLDL size can be significantly elevated.

Mean diameter of HDL particles. Larger HDL particles are more cardioprotective, associated with better reverse cholesterol transport capacity.

PED: AAS shrink HDL particles by reducing the proportion of large cardioprotective HDL. Smaller HDL is less effective at reverse cholesterol transport. Oral AAS have the most pronounced effect on HDL size. Regular aerobic exercise promotes larger HDL particles. HDL size typically recovers post-cycle alongside HDL-C and HDL-P.

NMR-derived composite score (0-100) reflecting insulin resistance based on lipoprotein particle sizes and concentrations. Higher scores indicate greater insulin resistance.

PED: GH use induces insulin resistance, directly elevating the LP-IR score. Exogenous insulin use (common in advanced bodybuilding) creates a complex picture — insulin sensitivity may be adequate but the lipoprotein profile reflects resistance patterns. Bulking phases with high carbohydrate intake worsen LP-IR. AAS themselves have variable effects on insulin sensitivity, but the combined GH + AAS + high-calorie diet profile commonly seen in bodybuilders often produces elevated LP-IR scores. This marker integrates information from VLDL, LDL, and HDL particle sizes and subclass concentrations.

Calculated ratio of LDL to HDL cholesterol. A higher ratio indicates greater atherogenic risk. Useful as a quick cardiovascular risk assessment.

PED: AAS dramatically worsen this ratio through a dual mechanism: elevating LDL while simultaneously suppressing HDL. Oral 17-alpha-alkylated steroids cause the most severe distortion — ratios of 5-10+ are common on-cycle (vs ideal <2.5). Trenbolone is particularly harsh. Even injectable testosterone at supraphysiological doses worsens this ratio. Post-cycle recovery of this ratio depends primarily on HDL recovery, which can take 3-6 months.

Cholesterol carried by VLDL particles, which transport triglycerides from the liver. Usually estimated from triglycerides via the Friedewald equation (Triglycerides / 5 in mg/dL). Elevated levels indicate excess triglyceride-rich lipoprotein production and increased atherogenic risk.

PED: Oral/17-alpha-alkylated AAS (oxandrolone, stanozolol, methandrostenolone) increase hepatic VLDL production while suppressing HDL, creating a broadly atherogenic profile. GH stimulates hepatic VLDL secretion by enhancing lipolysis and promoting insulin resistance. The combination of oral AAS + GH + high-calorie bulking diets creates maximal VLDL elevation through multiple converging pathways. Lipid effects from AAS are generally reversible, normalising 2.5 to 4 months after discontinuation.